LUNG CANCER

TRIPLEX finds thoracic radiotherapy with durvalumab chemo in ES-SCLC adds toxicity and deaths, without boosting survival.

LAURA trial safety update shows osimertinib after chemoradiotherapy in stage III EGFR-mutant NSCLC stays manageable, no new signals.

Ateganosine (THIO) plus cemiplimab shows 90.5% disease control in heavily pretreated NSCLC in phase 2 THIO-101 trial interim data (NCT05208944).

The next-generation KRAS G12C inhibitor improved survival vs the approved first-generation agents sotorasib and adagrasib.

ASCO 2026 data reshapes lung cancer care, highlighting durable ALK control, new EGFR options, bispecific first-line gains, and SCLC progress.

INSIGHT tests if NSCLC super-responders with pathologic complete response can skip adjuvant durvalumab, reducing toxicity without sacrificing survival.

Young women with lung cancer face stigma, misdiagnosis, trial underrepresentation, and missed fertility support—clinical gaps that delay care and worsen long-term outcomes.

The investigational ADC sigvotatug vedotin missed the primary OS endpoint vs docetaxel in phase 3 NSCLC trial, but showed stronger second-line benefit trends.

Dr Haigentz breaks down 3 practice-changing ASCO 2026 lung cancer abstracts, from adjuvant targeted therapy to ADCs reshaping the immunotherapy backbone.

How young women with lung cancer face stigma, misdiagnosis, and fertility gaps—plus the equity-driven approach reshaping care and trials.

Real-world claims data show alectinib beats crizotinib in ALK+ NSCLC survival, urging early use of newer ALK inhibitors.

Benjamin Herzberg, MD, highlights ASCO 2026's most exciting KRAS data, sequencing strategies, and emerging therapies for KRAS-mutant lung cancer.

During a live event, Bruna Pellini, MD, and participants discussed frontline treatment selection for patients with ROS1-positive advanced non–small cell lung cancer, including how evolving efficacy and tolerability data are shifting practice toward newer-generation TKIs.

Topline data show no overall survival advantage for lurbinectedin monotherapy or combination therapy over investigators' choice in second-line metastatic small cell lung cancer; drug's first-line maintenance approval remains intact.

Dr Ajaz Khan of City of Hope shares key ASCO 2026 takeaways, including giredestrant, selpercatinib, ivonescimab, and the rise of ctDNA and AI in oncology.

Merck and Gilead discontinue KEYNOTE-D46/EVOKE-03 after combination fails to demonstrate statistically significant progression-free survival benefit over pembrolizumab monotherapy

The phase 3 WU-KONG28 trial found that sunvozertinib decreased disease progression risk by 35% and nearly doubled response rates vs platinum-based chemotherapy in treatment-naive patients with NSCLC harboring EGFR exon 20 insertions.

ANK-101, an IL-12 anchored immunotherapy, is being studied with checkpoint blockade in patients with non–small cell lung cancer in a phase 1b trial.

FDA clears US enrollment for ateganosine plus cemiplimab in third-line NSCLC, testing telomere-targeting therapy after checkpoint and chemo failure.

FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal trials.

Learn how TMB, PD-L1, smoking, and tumor burden shape first-line lung cancer immunotherapy choices, including when to add chemo or CTLA-4.

"This is one of very few studies in advanced squamous NSCLC that has shown median survival beyond 2 years," said Shun Lu, MD, PhD.

"Adjuvant selpercatinib should be considered as a new standard of care in early-stage RET fusion–positive lung cancer,” said Jonathan Goldman, MD.

Phase 3 NEOTORCH shows perioperative toripalimab plus platinum chemo boosts event-free survival and responses in resectable stage II–III NSCLC.

FDA grants priority review to neladalkib for post-TKI ALK+ NSCLC, aiming to beat resistance and brain metastases; decision due Nov 27, 2026.